Naphazoline Hydrochloride/Chlorphenamine Maleate/Cyanocobalamin

Tier C — Watch / trade

Originator

1997

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：α-adrenoceptors, HRH1, MCM

Indications (approved)：Ophthalmic disease

Regional status

Phase II

2023-04-06

China

Approved

1997-01-01

Japan

Factories producing this API12

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

12 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Naphazoline Hydrochloride/Chlorphenamine Maleate/Cyanocobalamin?

Approved indications include: Ophthalmic disease.

When does the Naphazoline Hydrochloride/Chlorphenamine Maleate/Cyanocobalamin patent expire?

No public expiry year is available for Naphazoline Hydrochloride/Chlorphenamine Maleate/Cyanocobalamin yet; this page updates once verified.

How do I get a quote for Naphazoline Hydrochloride/Chlorphenamine Maleate/Cyanocobalamin intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27